ASCO Preview Highlights Study Of Alimta For First-Line NSCLC
This article was originally published in The Pink Sheet Daily
Executive Summary
Maintenance therapy with Lilly’s pemetrexed shows increase in progression-free survival in the only drug-related abstract in ASCO’s press call.
You may also be interested in...
Through Alimta Lens, OSI Views Positive Near-term Advantages For Tarceva In Lung Cancer
Approval of Lilly’s Alimta in first-line NSCLC and recent data showing it is ineffective in squamous histologies could give Tarceva a leg up in second-line setting.
Through Alimta Lens, OSI Views Positive Near-term Advantages For Tarceva In Lung Cancer
Approval of Lilly’s Alimta in first-line NSCLC and recent data showing it is ineffective in squamous histologies could give Tarceva a leg up in second-line setting.
Alimta Beats Gemcitabine In Some NSCLC Types
But Phase III results show similar efficacy in patients overall.